All pharmacology receptors with their uses with diagrams for inicet
Reading File
Pharmacology receptors is a huge topic for INICET - covering the entire autonomic, CNS, and hormonal receptor systems with their subtypes, agonists/antagonists, and clinical uses. Given the scope, here's a breakdown so we can go deep on one area at a time rather than a shallow dump of everything.
Topic Map: Pharmacology Receptors (High-Yield for INICET)
- Cholinergic receptors - Muscarinic (M1-M5) and Nicotinic (Nm, Nn) - drugs: atropine, pilocarpine, bethanechol, succinylcholine, neostigmine
- Adrenergic receptors - Alpha-1, Alpha-2, Beta-1, Beta-2, Beta-3 - drugs: adrenaline, noradrenaline, dobutamine, salbutamol, prazosin, propranolol
- Dopaminergic receptors - D1-D5 - drugs: levodopa, bromocriptine, antipsychotics (D2 blockers), metoclopramide
- Serotonergic (5-HT) receptors - 5-HT1 to 5-HT7 - drugs: triptans, ondansetron, buspirone, SSRIs, cisapride
- Histamine receptors - H1, H2, H3, H4 - drugs: antihistamines (cetirizine), ranitidine/omeprazole pathway, betahistine
- GABA receptors - GABA-A (ionotropic, benzodiazepine/barbiturate site) and GABA-B (metabotropic) - drugs: diazepam, phenobarbital, baclofen, flumazenil
- Opioid receptors - Mu, Kappa, Delta, ORL-1 - drugs: morphine, pentazocine, naloxone, buprenorphine
- Glutamate receptors - NMDA, AMPA, Kainate, Metabotropic - drugs: ketamine, memantine
- Steroid/nuclear hormone receptors - Glucocorticoid, mineralocorticoid, estrogen, androgen, thyroid receptors - relevant drugs and SERMs (tamoxifen, raloxifene)
- Other important receptors - Angiotensin (AT1/AT2 - losartan), Purinergic (P2Y12 - clopidogrel), Imidazoline, Adenosine, Cannabinoid (CB1/CB2), Insulin/Tyrosine kinase receptors
Each of these has classic INICET one-liners: receptor subtype, second messenger/G-protein coupling, location, agonist/antagonist drugs, and clinical use - plus diagrams (signal transduction pathways) work well as visuals.
Which one do you want me to go deep on first, with full subtype tables, mechanisms, drug lists, and diagrams?
Asking for Preferences
Which receptor system should I cover in full depth first (with subtype table, mechanisms, drugs, and diagrams)?
Pharmacology receptors is a huge topic for INICET - covering the entire autonomic, CNS, and hormonal receptor systems with their subtypes, agonists/antagonists, and clinical uses. Given the scope, here's a breakdown so we can go deep on one area at a time rather than a shallow dump of everything.
Topic Map: Pharmacology Receptors (High-Yield for INICET)
- Cholinergic receptors - Muscarinic (M1-M5) and Nicotinic (Nm, Nn) - drugs: atropine, pilocarpine, bethanechol, succinylcholine, neostigmine
- Adrenergic receptors - Alpha-1, Alpha-2, Beta-1, Beta-2, Beta-3 - drugs: adrenaline, noradrenaline, dobutamine, salbutamol, prazosin, propranolol
- Dopaminergic receptors - D1-D5 - drugs: levodopa, bromocriptine, antipsychotics (D2 blockers), metoclopramide
- Serotonergic (5-HT) receptors - 5-HT1 to 5-HT7 - drugs: triptans, ondansetron, buspirone, SSRIs, cisapride
- Histamine receptors - H1, H2, H3, H4 - drugs: antihistamines (cetirizine), ranitidine/omeprazole pathway, betahistine
- GABA receptors - GABA-A (ionotropic, benzodiazepine/barbiturate site) and GABA-B (metabotropic) - drugs: diazepam, phenobarbital, baclofen, flumazenil
- Opioid receptors - Mu, Kappa, Delta, ORL-1 - drugs: morphine, pentazocine, naloxone, buprenorphine
- Glutamate receptors - NMDA, AMPA, Kainate, Metabotropic - drugs: ketamine, memantine
- Steroid/nuclear hormone receptors - Glucocorticoid, mineralocorticoid, estrogen, androgen, thyroid receptors - relevant drugs and SERMs (tamoxifen, raloxifene)
- Other important receptors - Angiotensin (AT1/AT2 - losartan), Purinergic (P2Y12 - clopidogrel), Imidazoline, Adenosine, Cannabinoid (CB1/CB2), Insulin/Tyrosine kinase receptors
Each of these has classic INICET one-liners: receptor subtype, second messenger/G-protein coupling, location, agonist/antagonist drugs, and clinical use - plus diagrams (signal transduction pathways) work well as visuals.
Which one do you want me to go deep on first, with full subtype tables, mechanisms, drug lists, and diagrams?
Searching Images
adrenergic receptor subtypes signal transduction diagram alpha beta
Searching Images
GABA-A receptor structure benzodiazepine binding site diagram
Searching Images
opioid receptor mu kappa delta G protein coupled receptor diagram
Searching Images
dopamine receptor D1 D2 signal transduction diagram
Finding Sources
Searching Images
G protein coupled receptor mechanism diagram second messenger
Searching Images
ligand gated ion channel receptor diagram neurotransmitter
Finding Sources
Finding Sources
Pharmacology Receptors for INICET — High-Yield Complete Review
Receptors are broadly classified by their signal transduction mechanism: Ligand-gated ion channels (fast, ms), G-protein coupled receptors (GPCRs) (seconds), Enzyme-linked/tyrosine kinase receptors (minutes-hours), and Nuclear/intracellular receptors (hours-days, gene transcription).
1. Cholinergic Receptors
(Lippincott Illustrated Reviews Pharmacology; Guyton and Hall Physiology)
| Receptor | G-protein/Type | Location | Action | Agonist | Antagonist | Clinical Use |
|---|---|---|---|---|---|---|
| M1 | Gq | CNS, gastric parietal cells | ↑IP3/DAG | Pilocarpine, Bethanechol | Pirenzepine | Glaucoma (pilocarpine), peptic ulcer (pirenzepine) |
| M2 | Gi | Heart (SA/AV node) | ↓cAMP, ↓HR | Carbachol | Atropine | Atropine for bradycardia/organophosphate poisoning |
| M3 | Gq | Smooth muscle, glands, bladder | Contraction/secretion | Bethanechol | Tolterodine, Oxybutynin, Ipratropium | Urinary retention (bethanechol), overactive bladder & COPD/asthma (antimuscarinics) |
| Nm | Ligand-gated Na+/K+ channel | Skeletal muscle NMJ | Depolarization | Succinylcholine (agonist) | Vecuronium, Atracurium (antagonist) | Anesthesia - muscle relaxation, intubation |
| Nn | Ligand-gated | Autonomic ganglia, CNS | Depolarization | Nicotine | Hexamethonium, Trimethaphan | Ganglionic blockers - historically for hypertensive emergencies |
Key drugs: Anticholinesterases (neostigmine - myasthenia gravis, reversal of neuromuscular blockade; physostigmine - atropine/anticholinergic poisoning, glaucoma; donepezil/rivastigmine - Alzheimer's disease).
2. Adrenergic Receptors
(Barash Clinical Anesthesia; Miller's Anesthesia; Goodman & Gilman's)
| Receptor | G-protein | Location | Effect | Agonist | Antagonist | Clinical Use |
|---|---|---|---|---|---|---|
| α1 | Gq | Vascular smooth muscle, GU sphincter | Vasoconstriction | Phenylephrine, Noradrenaline | Prazosin, Tamsulosin | Hypotension/nasal decongestant (agonist); BPH, hypertension (antagonist) |
| α2 | Gi | Presynaptic nerve terminals, CNS, pancreas (β cells) | Feedback inhibition of NA release, sedation | Clonidine, Dexmedetomidine | Yohimbine | Hypertension, opioid withdrawal, sedation in ICU (dexmedetomidine) |
| β1 | Gs | Heart, kidney (JGA) | ↑HR, ↑contractility, renin release | Dobutamine | Metoprolol, Atenolol (cardioselective) | Cardiogenic shock/heart failure (agonist); MI, arrhythmia, heart failure, hypertension (antagonist) |
| β2 | Gs | Bronchi, uterus, vessels, skeletal muscle | Bronchodilation, vasodilation, tocolysis | Salbutamol, Terbutaline | Propranolol (non-selective) | Asthma/COPD (agonist); preterm labor (terbutaline); glaucoma, migraine prophylaxis, essential tremor (non-selective blockers) |
| β3 | Gs | Adipose tissue, bladder detrusor | Lipolysis, detrusor relaxation | Mirabegron | - | Overactive bladder |
3. Dopaminergic Receptors
(Kaplan & Sadock's Psychiatry; Goodman & Gilman's)
| Receptor | G-protein | Location | Clinical relevance |
|---|---|---|---|
| D1 (D1-like: D1, D5) | Gs | Striatum, renal vasculature | Renal vasodilation at low-dose dopamine |
| D2 (D2-like: D2, D3, D4) | Gi | Nigrostriatal, mesolimbic, mesocortical, CTZ (chemoreceptor trigger zone), anterior pituitary | Blocked by antipsychotics (haloperidol, risperidone) → antipsychotic effect but also extrapyramidal side effects and hyperprolactinemia; agonists (bromocriptine, pramipexole, ropinirole) used in Parkinson's disease and prolactinoma; D2 antagonism by metoclopramide/domperidone → antiemetic, prokinetic |
Levodopa/Carbidopa: converted to dopamine, mainstay of Parkinson's disease treatment.
4. Serotonergic (5-HT) Receptors
| Receptor | Type | Location/Use |
|---|---|---|
| 5-HT1A | Gi | Raphe nucleus autoreceptor - Buspirone (anxiolytic), used in generalized anxiety disorder |
| 5-HT1B/1D | Gi | Cranial vessels - Triptans (sumatriptan) for acute migraine |
| 5-HT2A | Gq | Cortex - blocked by atypical antipsychotics (risperidone, clozapine); LSD acts here |
| 5-HT3 | Ligand-gated ion channel (only ionotropic 5-HT receptor) | CTZ/gut - Ondansetron, Granisetron (antiemetics, esp. chemotherapy-induced vomiting) |
| 5-HT4 | Gs | GI tract - Cisapride, Prucalopride (prokinetics) |
SSRIs (fluoxetine, sertraline) work indirectly by blocking serotonin reuptake, increasing synaptic 5-HT across all subtypes - used in depression, OCD, anxiety disorders.
5. Histamine Receptors
| Receptor | G-protein | Location | Use |
|---|---|---|---|
| H1 | Gq | Bronchial/vascular smooth muscle, brain | Antihistamines (cetirizine, diphenhydramine) - allergy, motion sickness, sedation |
| H2 | Gs | Gastric parietal cells | Ranitidine, Famotidine - peptic ulcer disease, GERD |
| H3 | Gi | Presynaptic CNS | Betahistine (partial antagonist) - Meniere's disease |
| H4 | Gi | Bone marrow, immune cells | Investigational - pruritus, inflammation |
6. GABA Receptors
| Receptor | Type | Mechanism | Drugs | Use |
|---|---|---|---|---|
| GABA-A | Ligand-gated Cl- channel (ionotropic) | ↑Cl- influx, hyperpolarization; has distinct barbiturate and benzodiazepine allosteric sites | Benzodiazepines (diazepam, lorazepam), Barbiturates (phenobarbital), Flumazenil (antagonist) | Anxiety, seizures, insomnia, anesthesia induction; flumazenil for benzodiazepine overdose |
| GABA-B | Gi (metabotropic) | ↓cAMP, ↑K+ conductance | Baclofen | Spasticity (cerebral palsy, MS, spinal cord injury) |
7. Opioid Receptors
(Goodman & Gilman's; Lippincott Pharmacology; Bradley and Daroff's Neurology)
| Receptor | G-protein | Effect | Agonist | Antagonist | Use |
|---|---|---|---|---|---|
| Mu (μ) | Gi | Analgesia, euphoria, respiratory depression, constipation, miosis | Morphine, Fentanyl | Naloxone, Naltrexone | Severe pain, MI pain, anesthesia adjunct; naloxone for opioid overdose |
| Kappa (κ) | Gi | Analgesia (spinal), sedation, dysphoria, no respiratory depression | Pentazocine, Butorphanol | - | Analgesia with lower abuse potential |
| Delta (δ) | Gi | Analgesia, mood modulation | Enkephalins (endogenous) | - | Under research |
| ORL-1 (nociceptin) | Gi | Anti-analgesic modulation | Nociceptin | - | Research |
Buprenorphine: partial μ agonist + κ antagonist - opioid dependence treatment.
8. Glutamate Receptors
| Receptor | Type | Drug relevance |
|---|---|---|
| NMDA | Ligand-gated (Ca2+ influx), voltage-dependent Mg2+ block | Ketamine, PCP (antagonists) - dissociative anesthesia; Memantine - Alzheimer's disease |
| AMPA/Kainate | Ligand-gated (Na+/K+) | Perampanel (AMPA antagonist) - refractory epilepsy |
| Metabotropic (mGluR) | GPCR | Investigational in neuroprotection |
9. Steroid/Nuclear Receptors
Intracellular receptors acting on DNA response elements (slow onset, prolonged action):
- Glucocorticoid receptor - corticosteroids (prednisolone) - anti-inflammatory, immunosuppression, asthma, autoimmune disease
- Mineralocorticoid receptor - aldosterone; spironolactone/eplerenone (antagonists) - heart failure, hyperaldosteronism, resistant hypertension
- Estrogen receptor (ER) - SERMs: Tamoxifen (antagonist in breast, agonist in bone/endometrium) - breast cancer; Raloxifene - osteoporosis
- Androgen receptor - Finasteride (5-alpha reductase inhibitor, indirect), Flutamide/Bicalutamide (direct antagonists) - BPH, prostate cancer
- Thyroid hormone receptor - T3/T4 signaling; relevant to levothyroxine therapy
10. Other Important Receptors (frequently asked)
| Receptor | Type | Drug | Use |
|---|---|---|---|
| AT1 (Angiotensin II) | Gq | Losartan, Valsartan (ARBs) | Hypertension, heart failure, diabetic nephropathy |
| P2Y12 (ADP receptor on platelets) | Gi | Clopidogrel, Ticagrelor | Antiplatelet therapy, ACS, post-PCI |
| Imidazoline (I1) | - | Clonidine, Moxonidine | Hypertension |
| Adenosine (A1) | Gi | Adenosine (drug itself) | Paroxysmal SVT termination |
| Cannabinoid (CB1/CB2) | Gi | Δ9-THC, Rimonabant | CB1 antagonist trialed for obesity (withdrawn - psychiatric effects) |
| Insulin receptor | Tyrosine kinase | Insulin | Diabetes mellitus |
| Growth hormone/Cytokine receptors | JAK-STAT | Tofacitinib (JAK inhibitor) | Rheumatoid arthritis |
Quick Recall Trick (INICET favorite)
"Qi-Qs-Qi-Qs" G-protein mnemonic for coupling: Gq → phospholipase C → IP3/DAG (α1, M1/M3, H1, V1, 5-HT2); Gs → ↑cAMP (β1/β2, D1, H2, V2, 5-HT4); Gi → ↓cAMP (α2, M2, D2, 5-HT1, opioid, GABA-B).
Recent evidence check: I ran a supplementary search for high-quality recent reviews on these classical receptor pharmacology topics — no new meta-analyses or systematic reviews were found that would revise this well-established classical pharmacology (it is textbook-stable content, not an area of active clinical trial revision).
If you want, I can go deeper into any single receptor family above with detailed subtype-selectivity tables, exam MCQs, or additional labeled diagrams — just tell me which one.
This is a shared conversation. Sign in to Orris to start your own chat.